Balyasny Asset Management LLC Avidity Biosciences, Inc. Transaction History
Balyasny Asset Management LLC
- $63.6 Billion
- Q4 2024
A detailed history of Balyasny Asset Management LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 137,057 shares of RNA stock, worth $4.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
137,057
Previous 160,809
14.77%
Holding current value
$4.4 Million
Previous $7.39 Million
46.04%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding RNA
# of Institutions
258Shares Held
108MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$355 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$303 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$277 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$260 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$255 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.67B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...